Benefit/risk ratio of Renzapride not sufficient to warrant further study in IBS-C
04/07/10 01:32 PM
Loc: Seattle, WA
Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation – a double-blind, randomized, placebo-controlled, study
A. J. LEMBO*, F. CREMONINI*, N. MEYERS† & R. HICKLING†
*Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, MA, USA ; †Alizyme Therapeutics Ltd, Cambridge, UK
Correspondence to Dr A. J. Lembo, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Rabb/Rose 1, Boston, MA 02215, USA.
Copyright Journal compilation © 2010 Blackwell Publishing Ltd
Aliment Pharmacol Ther 31, 979–990
Renzapride, a 5-hydroxytryptamine type-4 (5-HT4) receptor agonist and 5-HT3 receptor antagonist, has been proposed as a new treatment of irritable bowel syndrome with constipation (IBS-C).
To assess the efficacy and safety of renzapride in women with IBS-C.
Women with IBS-C were randomized to renzapride 4 mg daily, 2 mg b.d. or placebo for 12 weeks. The primary outcome measure was global relief of IBS symptoms. A subset of patients were enrolled in a 12-month, open-label study of renzapride 4 mg daily.
A total of 1798 patients were included in the efficacy analysis and 971 patients entered the long-term study. The mean (S.E.M.) number of months with relief of overall IBS symptoms was 0.55 (0.04), 0.60 (0.04) and 0.44 (0.04) in the renzapride 4 mg daily, 2 mg b.d. and placebo groups (P = 0.027 and P = 0.004 respectively). Small yet statistically significant differences in favour of renzapride were observed on stool consistency and frequency, and bloating/abdominal distension scores. Renzapride was generally well tolerated; however, three episodes of ischaemic colitis were reported in the long-term study.
Given the limited increase in efficacy over placebo and the incidence of ischaemic colitis observed, our data suggest that the benefit/risk ratio of renzapride is not sufficient to warrant further study in IBS-C.
Publication data Submitted 9 November 2009 First decision 30 November 2009 Resubmitted 8 February 2010 Accepted 10 February 2010 Epub Accepted Article 16 February 2010
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!